Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Return on Equity (2021 - 2025)

GeneDx Holdings (WGS) has disclosed Return on Equity for 5 consecutive years, with 0.07% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Equity rose 16.0% to 0.07% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.07%, a 16.0% increase, with the full-year FY2025 number at 0.08%, up 15.0% from a year prior.
  • Return on Equity was 0.07% for Q4 2025 at GeneDx Holdings, down from 0.01% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 4.99% in Q3 2021 to a low of 1.83% in Q1 2023.
  • A 5-year average of 0.32% and a median of 0.53% in 2022 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: tumbled -546bps in 2022, then surged 125bps in 2024.
  • GeneDx Holdings' Return on Equity stood at 1.12% in 2021, then dropped by -20bps to 1.35% in 2022, then surged by 46bps to 0.73% in 2023, then skyrocketed by 68bps to 0.23% in 2024, then skyrocketed by 70bps to 0.07% in 2025.
  • Per Business Quant, the three most recent readings for WGS's Return on Equity are 0.07% (Q4 2025), 0.01% (Q3 2025), and 0.01% (Q2 2025).